The psychoneuroendocrine-immunotherapy of cancer: Historical evolution and clinical results

Paolo Lissoni, Giusy Messina, Arianna Lissoni, Rovelli Franco, Paolo Lissoni, Giusy Messina, Arianna Lissoni, Rovelli Franco

Abstract

The prognosis of the neoplastic diseases depends not only on the biogenetic characteristics of cancer cells but also on the immunological response of patients, which may influence the biological features of cancer cells themselves as well as the angiogenic processes. Moreover, the immune system in vivo is under a physiological psychoneuroendocrine (PNE) regulation, mainly mediated by the brain opioid system and the pineal gland. In more detail, the anticancer immunity is stimulated by the pineal hormone melatonin (MLT) and inhibited by the opioid system, namely, through a mu-opioid receptor. Several alterations involving the pineal endocrine function and the opioid system have been described in cancer patients, which could play a role in tumor progression itself. Therefore, the pharmacological correction of cancer progression-related anomalies could contribute to control cancer diffusion, namely, the pineal endocrine deficiency and the hyperactivity of brain opioid system. In fact, the administration of pharmacological doses of the only MLT has already been proven to prolong the 1-year survival in untreatable metastatic cancer patients. Better results may be achieved by associating other pineal indoles to MLT, mu-opioid antagonists, cannabinoids, beta-carbolines. Moreover, these neuroendocrine combinations may be successfully associated with antitumor cytokines, such as interleukin (IL)-2 and IL-12, as a PNE-immune cancer therapy as well as with antitumor plants as PNE-phytotherapy of cancer in an attempt to propose possible anticancer treatments also to patients with disseminated cancer and untreatable according to the standard oncology.

Keywords: Cancer disease; pineal glande; psychoneuroimmunology.

Conflict of interest statement

The authors have no conflicts of interest.

References

    1. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science. 1981;212:1100–9.
    1. Foon KA. Biological response modifiers: The new immunotherapy. Cancer Res. 1989;49:1621–39.
    1. Lissoni P, Barni S, Rovelli F, Tancini G. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology. 1991;48:125–7.
    1. Antoni MH. Psychoneuroendocrinology and psychoneuroimmunology of cancer: Plausible mechanisms worth pursuing? Brain Behav Immun. 2003;17(Suppl 1):S84–91.
    1. Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993;14:1–10.
    1. Lissoni P. The pineal gland as a central regulator of cytokine network. Neuro Endocrinol Lett. 1999;20:343–9.
    1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.
    1. Mormont MC, Lévi F. Circadian-system alterations during cancer processes: A review. Int J Cancer. 1997;70:241–7.
    1. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer. 1984;34:323–8.
    1. Maestroni GJ, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci. 1988;521:140–8.
    1. Danielczyk K, Dziegiel P. MT1 melatonin receptors and their role in the oncostatic action of melatonin. Postepy Hig Med Dosw. 2009;63:425–34.
    1. Cos S, Fernández R. Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells. J Pineal Res. 2000;29:166–71.
    1. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther. 2009;8:337–46.
    1. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res. 2010;48:178–84.
    1. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: A multitasking molecule. Prog Brain Res. 2010;181:127–51.
    1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–41.
    1. King IL, Segal BM. Cutting edge: IL-12 induces CD4+ CD25- T cell activation in the presence of T regulatory cells. J Immunol. 2005;175:641–5.
    1. Thornton AM, Shevach EM. Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–90.
    1. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol. 2002;2:389–400.
    1. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008;27:5886–93.
    1. Lewis JW, Shavit Y, Terman GW, Nelson LR, Gale RP, Liebeskind JC. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides. 1983;4:635–8.
    1. Buswell RS. Letter: The pineal and neoplasia. Lancet. 1975;1:34–5.
    1. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem. 2002;2:167–79.
    1. Lissoni P, Resentini M, Mauri R, Esposti D, Esposti G, Rossi D, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res. 1986;18:77–8.
    1. Sacerdote P, Panerai AE. Role of opioids in the modulation of the TH1/TH2 responses. Neuroimmunomodulation. 1999;6:422–3.
    1. Lapin V. Pineal gland and malignancy. Osterr Z Onkol. 1976;3:51–60.
    1. El-Domeiri AA, Das Gupta TK. Reversal by melatonin of the effect of pinealectomy on tumor growth. Cancer Res. 1973;33:2830–3.
    1. Starr KW. Growth and new growth: Environmental carcinogens in the process of human ontogeny. Prog Clin Cancer. 1970;4:1–29.
    1. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci. 1994;741:1–38.
    1. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–95.
    1. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015;10:974–84.
    1. Regelson W, Pierpaoli W. Melatonin: A rediscovered antitumor hormone? Its relation to surface receptors; sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy. Cancer Invest. 1987;5:379–85.
    1. Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res. 1993;14:27–33.
    1. Cao R, Peng W, Wang Z, Xu A. Beta-carboline alkaloids: Biochemical and pharmacological functions. Curr Med Chem. 2007;14:479–500.
    1. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer. 2002;10:110–6.
    1. Bartsch H, Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm. 1981;52:269–79.
    1. Lissoni P, Mandalà M, Mandelli A, Fumagalli L. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus the pineal oncostatic hormones melatonin and 5-methoxytryptamine in untreatable advanced solid neoplasm patients with very poor clinical status. Int J Immunother. 1999;XV:35–8.
    1. Plotnikoff NP, Miller GC. Enkephalins as immunomodulators. Int J Immunopharmacol. 1983;5:437–41.
    1. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004;25:14–23.
    1. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39:360–6.
    1. Lissoni P, Porro G, Messina G, Porta E, Rovelli F, Roselli MG, et al. Morphine, melatoninm marijuana, magnolia and myrrh as the five M schedule in the treatment of cancer pain and the possible dose-dependency of the antitumor and analgesic effects of the pineal hormone melatonin. Anticancer Res. 2014;34:6033–4.
    1. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integr Cancer Ther. 2009;8:416–22.
    1. Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002;23:255–8.
    1. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53:43–6.
    1. Guo JM, Xiao BX, Liu Q, Zhang S, Liu DH, Gong ZH. Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol Sin. 2007;28:1991–5.
    1. Hanus LO, Rezanka T, Dembitsky VM, Moussaieff A. Myrrh – Commiphora chemistry. Biomed Pap. 2005;149:3–27.
    1. Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009;11:1139–48.
    1. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, et al. Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 2008;28:1377–81.
    1. Lissoni P, Pittalis S, Rovelli F, Vigorè L, Roselli MG, Brivio F. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer. J Biol Regul Homeost Agents. 1995;9:63–6.
    1. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus Aloe vera in untreatable advanced solid neoplasms. Nat Immun. 1998;16:27–33.
    1. Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:85–96.
    1. Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27:1199–206.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する